The median PFS of the patients with plasma KRAS mutations was 1.6 months (95 % CI, 0.1–3.1), a result that was comparable with the PFS of patients with tumor-tissue KRAS mutations (median PFS, 1.8 months [95 % CI, 0.0–3.6]). This evidence concerns the gene KRAS and neoplasm.